The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following ...

PD-L1 expression predicts better outcomes with nivolumab and ipilimumab in ccRCC, aligning with previous trial results. High KIM-1 expression is linked to worse DFS, suggesting its potential as a ...

During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...

Adjuvant Opdivo showed a significant improvement in overall survival and disease-free survival for patients with high-risk ...

Discover which therapies are expected to grab the PD/L-1 Market Share @ PD/L-1 Treatment Market Size ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

While checkpoint inhibitors such as nivolumab (Opdivo) and Keytruda appear to work best for patients with high PD-L1 expression, CEL-SCI’s Multikine has been shown to be more effective in ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Course and the session Metastatic ...

The EC has approved BeiGene’s PD-1 inhibitor Tevimbra in combination with chemotherapy to treat ESCC and G/GEJ adenocarcinoma ...